IBS PROfiler® USA

There is certainly a lot going on in the area of irritable bowel syndrome (IBS).

No wonder, as IBS is said to make up about 12% of all PCP visits, and up to 30% of all gastroenterologist visits are said to be IBS-related. Furthermore, IBS is said to be one of the main causes of missed work days in the U.S.

IBS is a broad label covering many symptoms and causes; there are literally hundreds of different ways to treat IBS, including various diets, supplements, and other OTC products and prescription IBS medications.

Accounting for prescription medications alone, more than 30 pharma and biotech companies either have IBS products out on the market (i.e., Alosetron (Lotronex), Tegaserod (Zelnet), LINZESS (linaclotide), Donnatol) or have products in clinical trials (i.e., Zemcolo. Blautix, LX1033, Bekinda).

It is an exciting field.

  • The different forms of IBS, IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and mixed IBS (IBS-M), require different treatment approaches.
  • Various substances with different modes of action (MOAs) are being researched to finally get a good handle on IBS management (i.e., probiotics, antibiotics, antidepressants, substances activating or blocking receptors to the central nervous system, and 5-HT3 or 4 antagonists).
  • Different sub-populations of patients are studied (i.e., adults in general with chronic constipation or diarrhea, women only with IBS-D or IBS-C, and children suffering from all forms of IBS).
  • Multiple clinical end-points need to be considered (i.e., pain, discomfort, gas, bloating, and bowel functions).

The IBS PROfiler® will answer questions like:

  • What are the caseloads of patients with different IBS forms?
  • What shares of current patients by IBS form are treated with diet only, with OTC products, or with prescription medications?
  • What shares of IBS patients are in need of treatment change or due for initiation of first-ever RX product?
  • How many IBS patients on RX products are in need of change of their IBS prescription product, wanting to use another IBS treatment, or not in need of change of their current IBS product?
  • What is the share of “uncontrolled” IBS patients?
  • What are the drivers of treatment initiations and changes, and what is their relative importance?
  • What are the greatest unmet needs in treatment of IBS-D, IBS-C, and IBS-M?
  • How is access to IBS agents currently steered toward or away from RX products?

The IBS PROfiler® will deliver results such as shares of IBS RX product users in need of changing their current treatment.

The PROfiler® methodology has successfully been used to explore the hyperphosphatemia and hyperkalemia markets in the U.S. and in Japan.

Its purpose is to provide critical and actionable market segmentation.

The PROfiler® methodology and reporting system provides critical and actionable market segmentation in complex markets beyond classical marketing research approaches.

The IBS-PROfiler® takes a Fresh Look at the IBS Market in the US.

10-15
respondents

Discovery Phase

Qualitative | Gastroenterologists — PCPs — IBS-C & D patients

250 HCPs
350 IBS-patients

Quantitative PROfiling

Bi-directional | Online | IBS patients & HCPs

Desk research by native-speaking experts

Sizing of Natural Patient Segments & High-Level Market Potential Estimate

Heat Map Provision of Actionable Patient Segments Overlaid with Real-World Data

The PROfiler® Methodology is Refined to Carve out Much-Needed New Analytical Perspectives.

Modular Design

PROfiler® is modular in design and iterative in function for stepwise generation of data and insights.

Bi-directional Analysis

PROfiler® simultaneously navigates the interactions driven by patients and their HCPs.

Hybrid Data Collection

PROfiler® uses tools to uncover and weigh drivers and barriers that may have been regarded as irrelevant.

Actionable Results

PROfiler® highlights correlations across factors such as QoL, prescribing patterns, health insurance and product capabilities.